{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T18:35:21Z","timestamp":1767206121981,"version":"build-2238731810"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Low-density lipoprotein cholesterol (LDL-C) has now been the primary target for lipid-lowering therapy in the European and US guidelines for the management of dyslipidemia, with increasing interest in apolipoprotein B (ApoB) as a secondary target. The relationship between ApoB and the severity of acute myocardial infarction as well as residual risk still needs to be further determined. Coronary atherosclerosis occurs as a result of a complex set of factors, and there is a strong relationship between insulin resistance and cardiovascular disease. In contrast, there are limited studies on the relationship between TyG index (triglyceride glucose index), an indicator of insulin resistance, and cardiovascular disease. The purpose of this study was to investigate the value of ApoB and TyG index in assessing the severity of myocardial infarction and predicting prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included 712 participants with acute myocardial infarction for a 5-year follow-up. Spearman correlation analysis and generalized linear model analysis were used to assess the correlation between ApoB and the severity of coronary atherosclerosis. Risk regression analysis was used to assess the correlation between ApoB and residual risk in patients with acute myocardial infarction, and the C-statistic, net reclassification index (NRI), and integrated discriminant improvement index (IDI) were further calculated to assess the predictive value of ApoB for residual risk after myocardial infarction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Categorizing apoB, LDL-C, and TyG indices according to tertiles, higher levels of ApoB were significantly associated with the severity of coronary artery stenosis in patients with acute myocardial infarction (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;0.001), whereas no such associations were found for elevated levels of LDL-C and TyG indices (\n                      <jats:italic>P &amp;gt;<\/jats:italic>\n                      0.05). Higher levels of apoB were significantly associated with residual risk of coronary atherosclerotic heart disease after full adjustment for confounders. Higher levels of ApoB were significantly associated with residual risk of coronary atherosclerotic heart disease by binary logistic regression analysis after complete adjustment for confounders. In multivariate variable-adjusted models, the OR and 95% CI for intermediate levels of ApoB (0.85-1.05 g\/L) compared with low levels of ApoB (\u22640.84 g\/L) and residual risk after myocardial infarction was 2.06 (1.11, 3.81) (P&amp;lt;0.05), and for high levels of ApoB (\u22651.06 g\/L) the OR and 95% CI was 2.60 (1.29, 5.26) (P &amp;lt; 0.05); for each SD increase in ApoB level, the increase in residual risk after myocardial infarction would increase 4.75-fold (P = 0.001). Higher levels of TyG index were not found to be significantly associated with residual risk after myocardial infarction (P &amp;gt; 0.05). The inclusion of LDL-C, ApoB, and TyG indices in the constructed baseline risk model, and ApoB significantly improved the predictive ability of the traditional risk model for residual risk. The ROC curve of the baseline risk model showed an AUC of 0.649; the AUC after adding LDL-C to the model was 0.680 (\n                      <jats:italic>P<\/jats:italic>\n                      =0.05684); the AUC after adding TyG to the model was 0.663 (\n                      <jats:italic>P<\/jats:italic>\n                      =0.1635); and the addition of ApoB to the baseline model increased the AUC substantially to 0.702 (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.00417). Inclusion of ApoB in the baseline risk model improved the prediction of MACE most significantly in the baseline model (net reclassification index [NRI]: 0.3324,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001; integrated discriminant improvement index [IDI]: 0.0414,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001); with the inclusion of LDL-C the NRI was 0.3218 (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), and IDI was 0.0263 (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001); NRI after inclusion of TyG index was 0.2169 (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.017); IDI was 0.0082 (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.022).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ApoB is an independent risk factor for major adverse cardiovascular events (MACE) following myocardial infarction. Elevated ApoB levels are more advantageous than elevated LDL-C levels in assessing the severity of coronary artery stenosis in myocardial infarction patients and predicting residual risk after myocardial infarction. Therefore, in patients with acute myocardial infarction, ApoB can be considered to guide further intensive treatment. However, the TyG index did not demonstrate a significant advantage in predicting cardiovascular residual risk in this study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1542190","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T04:11:10Z","timestamp":1756786270000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Correlation analysis of ApoB and TyG index levels with residual cardiovascular risk in patients with acute myocardial infarction"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuanyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dachuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101622","DOI":"10.1016\/j.cpcardiol.2023.101622","article-title":"Global cardiovascular diseases death rate prediction","volume":"48","author":"Gaidai","year":"2023","journal-title":"Curr problems Cardiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406656","article-title":"Demographic and epidemiologic drivers of global cardiovascular mortality","volume":"372","author":"Roth","year":"2015","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae258","article-title":"Discordance among apoB, non\u2013high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention","volume":"45","author":"Sniderman","year":"2024","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.025858","article-title":"Physiological bases for the superiority of apolipoprotein b over low-density lipoprotein cholesterol and non\u2013high-density lipoprotein cholesterol as a marker of cardiovascular risk","volume":"11","author":"Glavinovic","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.14336\/AD.2021.0929","article-title":"The functional role of lipoproteins in atherosclerosis: novel directions for diagnosis and targeting therapy","volume":"13","author":"Lu","year":"2022","journal-title":"Aging Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of apolipoprotein B\u2013containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content","volume":"7","author":"Marston","year":"2022","journal-title":"JAMA Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-018-0762-4","article-title":"Association between insulin resistance and the development of cardiovascular disease","volume":"17","author":"Ormazabal","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-020-01210-5","article-title":"Triglyceride\u2013glucose index is associated with the risk of myocardial infarction: an 11-year prospective study in the Kailuan cohort","volume":"20","author":"Tian","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-016-0324-2","article-title":"Triglyceride glucose index, a marker of insulin resistance, is associated with coronary artery stenosis in asymptomatic subjects with type 2 diabetes","volume":"15","author":"Lee","year":"2016","journal-title":"Lipids Health Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.11909\/j.issn.1671-5411.2019.03.014","article-title":"2018 Chinese guidelines for prevention and treatment of hypertension-A report of the revision committee of Chinese guidelines for prevention and treatment of hypertension","volume":"16","author":"Liu","year":"2019","journal-title":"J Geriatric Cardiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes\u20142021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/met.2008.0034","article-title":"The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects","volume":"6","author":"Simental-Mend","year":"2008","journal-title":"Metab syndrome related Disord"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-021-01268-9","article-title":"Triglyceride\u2013glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies","volume":"20","author":"Ding","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2016.46.5.639","article-title":"Association between the gensini score and carotid artery stenosis","volume":"46","author":"Avci","year":"2016","journal-title":"Korean Circ J"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.1007\/978-90-368-0980-1","volume-title":"ApoB in clinical care","author":"De Graaf","year":"2015"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C\u2013lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"Jama"},{"key":"B21","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41598-017-00499-9","article-title":"Novel and traditional lipid-related biomarkers and their combinations in predicting coronary severity","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/1354750X.2018.1474256","article-title":"Low-density lipoprotein-associated variables and the severity of coronary artery disease: an untreated Chinese cohort study","volume":"23","author":"Zhao","year":"2018","journal-title":"Biomarkers"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.865863","article-title":"Residual risk of coronary atherosclerotic heart disease and severity of coronary atherosclerosis assessed by ApoB and LDL-C in participants with statin treatment: a retrospective cohort study","volume":"13","author":"Yao","year":"2022","journal-title":"Front Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000625","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/hc3501.095214","article-title":"Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins AI and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study","volume":"104","author":"Sharrett","year":"2001","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.3389\/fendo.2025.1699149","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000}}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1542190\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T13:25:08Z","timestamp":1757942708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1542190\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":27,"alternative-id":["10.3389\/fendo.2025.1542190"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1542190","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"article-number":"1542190"}}